Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Uterine leiomyosarcoma (ULMS) is an aggressive malignancy with limited therapeutic options and poor patient prognosis.
• Current chemotherapy regimens demonstrate minimal efficacy against ULMS, necessitating the identification of novel therapeutic targets.

Purpose of the Study:

• To identify novel therapeutic targets for uterine leiomyosarcoma (ULMS) by screening a library of FDA-approved drugs.
• To investigate the role of uncoupling protein 2 (UCP2) in ULMS pathogenesis and its potential as a therapeutic target.

Main Methods:

• A three-step screening process utilizing a chemical library of 1271 FDA-approved drugs to evaluate inhibitory effects on ULMS cells.
• Establishment of mouse models through subcutaneous or orthotopic transplantation of SK-UT-1 cells for in vivo efficacy assessment.
• mRNA sequencing to analyze gene expression changes, focusing on the sirtuin signaling pathway and reactive oxygen species (ROS) induction.

Main Results:

• Proscillaridin A and lanatoside C demonstrated superior antitumor effects in vivo.
• Downregulation of uncoupling protein 2 (UCP2) suppressed ULMS cell growth by increasing ROS.
• UCP2 expression was significantly upregulated in ULMS tissues compared to myoma tissues at both RNA and protein levels.

Conclusions:

• Proscillaridin A and lanatoside C are potential drug candidates for ULMS treatment.
• Uncoupling protein 2 (UCP2) is identified as a key factor in ULMS progression and a promising therapeutic target.
• Targeting UCP2 may offer a novel therapeutic strategy for patients diagnosed with uterine leiomyosarcoma.